Pharmaceutical contract manufacturing: the site goes on your authorisation

Responsibility does not travel with the batch

The authorisation holder answers for safety, efficacy and quality, including for work performed at a site it neither owns nor staffs. That obligation extends to knowing how the manufacturer operates: which deviations occurred, what changes were made, how complaints were handled, whether suppliers of starting materials were themselves assessed. Regulators expect the oversight to be exercised and documented, not merely contracted for. Firms treating an external manufacturer as a sealed box producing compliant cartons find the gap during an inspection, when questions are addressed to them and every answer lives in somebody else's building.

The site is written into the authorisation

Manufacturing locations are named in the dossier, so production cannot simply move because a commercial relationship soured. Adding a site, replacing one, or altering the process at an existing one requires a variation supported by data and assessed on the regulator's timetable rather than yours. That timetable is the single biggest constraint on supply flexibility in this sector, and it explains why a second approved site earns its cost long before anybody needs it. Companies realising they want an alternative in the middle of a supply failure are usually far from being able to use one.

Scale, equipment train and the comparability question

A process validated on one set of equipment does not automatically behave identically on another. Dryer geometry, blender type, press design, filling technology and even the material of a transfer line can shift dissolution, particle characteristics, impurity profile or stability. What has to be shown is not that the new site followed the method, but that the product it makes is genuinely equivalent to the one already authorised. Generating that evidence takes engineering batches, analytical work and calendar time, and underestimating it is the most dependable way to miss a launch.

Release, and the person who signs it

Batches reach the market only once a qualified individual, in whichever role a jurisdiction defines, certifies that each was made and checked in accordance with the authorisation. Where that person sits — at the manufacturer, inside your organisation, or at a third party — determines who physically holds the documentation, how fast stock can be released, and what happens when a deviation surfaces late. It also determines who is able to say no. A release function inside the company that made the batch is common and workable, and the independence arrangements permitting it to refuse are worth understanding.

Campaigns, capacity and the queue you are joining

Sterile and specialised capacity is scarce, and sites plan production in campaigns with changeover and cleaning validation between products. Your requirement is being fitted into a sequence built around larger customers, and modest volume with irregular timing is an awkward guest whatever price is offered. Planning consequences follow: order well ahead, expect campaign quantities exceeding immediate demand, and hold stock accordingly. The negotiation that matters is rarely price per unit. It is the reservation of capacity slots, and what becomes of them when your forecast moves.

Frequently asked questions

How quickly could we move a licensed product to another site?

More slowly than commercial logic suggests. Beyond the technical transfer and the demonstration of comparability, the change needs a variation to the authorisation, assessed by regulators on their own schedule and in several markets on several schedules at once. Planning for that horizon means qualifying an alternative before there is a problem and holding stock cover matched to approval timelines rather than to production lead time. Companies that wait for a crisis rarely have room to manoeuvre.

Who releases the batch to market, us or the manufacturer?

Whoever holds the certifying role under your quality arrangements, which is a decision to take deliberately rather than to inherit. Manufacturers routinely provide it, which is efficient and keeps documentation where it was generated. Holding it yourself gives direct control over what ships and forces your own people to read the batch record. Either way the authorisation holder stays accountable, so the arrangement must include full access to records, deviation reports and any investigation touching your product.

Do inspections of our contract manufacturer involve us?

Frequently, yes. Inspectors examine how an authorisation holder oversees outsourced work, so findings at a manufacturing site generate questions aimed at your quality system: how you approved them, what you monitor, how deviations reach you, whether your periodic review of the arrangement is genuine. Expect to be asked for evidence of oversight rather than assurances about it. Organisations that have never visited the site they depend on find that a difficult conversation.